Neuroinflammation Hypothesis and Alzheimer’s Disease
DOI:
https://doi.org/10.61173/j1z79349Keywords:
Alzheimer’s disease, neuroinflammation, microglia, treatmentAbstract
A serious, long-term degenerative neurological disease in humans is one definition of Alzheimer’s disease (AD). AD brain areas that are pathologically sensitive exhibit inflammation, and this inflammation carries with it all the complexity of peripheral local inflammatory responses. Degenerating tissue and the buildup of very insoluble aberrant materials are two traditional causes of peripheral inflammation. Nowadays, the inhibitors which were discovered before cannot have a good effect on the treatment to the growth of this disease. This article provides an overview of how microglia-mediated neuroinflammation affects AD, with particular attention to the pathogenic process of microglia, and the potential and recent developments in neuroinflammation as an AD diagnostic and treatment target. Therefore, even if clinical research and animal models are still in their infancy, they clearly imply that AD inflammation plays a major role in AD pathogenesis. Gaining more insight into the immunoregulatory and inflammatory mechanisms underlying AD should make it feasible to create anti-inflammatory treatments that, while probably not curative, will at least assist postpone the start or decrease the disease’s terrible course.References
while active PPAR-γ itself may suppress the inflammatory hypothesis. Nat Neurosci (2015) 18(6):794–9. response. [29]. [2] Lecca D, Jung YJ, Scerba MT, Hwang I, Kim YK, Kim S, Modrow S, Tweedie D, Hsueh SC, Liu D, Luo W, Glotfelty E, 4.4 Future Prospect Li Y, Wang JY, Luo Y, Hoffer BJ, Kim DS, McDevitt RA, Greig Patient therapy is still difficult due to the intricacy of AD. NH. Role of chronic neuroinflammation in neuroplasticity and Memantine and cholinesterase inhibitors, or these two cognitive function: A hypothesis. Alzheimers Dement. 2022 drugs combined, are the only approved treatments for Nov;18(11):2327-2340. AD at the moment. On top of that, a considerable number [3] Wang C, Zong S, Cui X, Wang X, Wu S, Wang L, Liu Y, Lu of novel pharmaceuticals have been unsuccessful in the Z. The effects of microglia-associated neuroinflammation on larger phase III clinical trials., failing to satisfy efficacy Alzheimer‘s disease. Front Immunol. 2023 Feb 22;14:1117172. endpoints, despite early promise. The complex aetiologia [4] Conti Filho CE, Loss LB, Marcolongo-Pereira C, Rossoni of AD, the present limitations in our understanding of Junior JV, Barcelos RM, Chiarelli-Neto O, da Silva BS, the links between the different pathways involved in the Passamani Ambrosio R, Castro FCAQ, Teixeira SF, Mezzomo development of Alzheimer’s disease and the ensuing neu- NJ. Advances in Alzheimer‘s disease‘s pharmacological rodegeneration, and the potential inefficacy of the existing treatment. Front Pharmacol. 2023 Jan 26;14:1101452. therapeutic modalities are the primary factors contributing [5] Stancu IC, Cremers N, Vanrusselt H, Couturier J, to the high attrition rate observed in AD-related clinical Vanoosthuyse A, Kessels S, et al.. Aggregated tau activates trials. Even if the combination of memantine and cholin- NLRP3-ASC inflammasome exacerbating exogenously seeded esterase inhibitors hasn’t worked well for treating AD, it’s and non-exogenously seeded tau pathology in vivo. Acta
possible that treating several routes will be necessary for Neuropathol (2019) 137(4):599–617. effective care. Thus, more experiments examining rational [6] Leuti A, Fazio D, Fava M, Piccoli A, Oddi S, Maccarrone M. agent combinations ought to be carried out in the future Bioactive lipids, inflammation and chronic diseases. Adv Drug [30]. Delivery Rev(2020) 159:133–69. Dean&Francis ISSN 2959-409X [7] Ueno M, Fujita Y, Tanaka T, Nakamura Y, Kikuta J, Ishii M, and perspectives. Genet. Med. Off. J. Am. Coll. Med Genet. et al.. Layer V cortical neurons require microglial support for 2016;18:421–430.
survival during postnatal development. Nat Neurosci (2013) [20] Wainaina M.N., Chen Z., Zhong C. Environmental factors 16(5):543–51. in the development and progression of late-onset Alzheimer’s [8] Salter M.W., Stevens B. Microglia emerge as central players disease. Neurosci. Bull. 2014;30:253–270. in brain disease. Nat. Med. 2017;23:1018–1027. [21] Moulton P.V., Yang W. Air pollution, oxidative [9] Kamphuis W., Kooijman L., Schetters S., Orre M., Hol stress, and Alzheimer’s disease. J. Environ. Public Health. E.M. Transcriptional profiling of CD11c-positive microglia 2012;2012:472751. . accumulating around amyloid plaques in a mouse model for [22] Hu N., Yu J.T., Tan L., Wang Y.L., Sun L., Tan L. Alzheimer’s disease. Biochim. Biophys. Acta. 2016;1862:1847– Nutrition and the risk of Alzheimer’s disease. Biomed. Res. Int. 1860. 2013;2013:524820. [10] Sarlus H., Heneka M.T. Microglia in Alzheimer’s disease. J. [23] Koyama A., Hashimoto M., Tanaka H., Fujise N., Clin. Investig. 2017;127:3240–3249. Matsushita M., Miyagawa Y., Hatada Y., Fukuhara R., [11] Qin Q., Teng Z., Liu C., Li Q., Yin Y., Tang Y. TREM2, Hasegawa N., Todani S., et al. Malnutrition in Alzheimer’s microglia, and Alzheimer’s disease. Mech. Ageing Dev. disease, dementia with lewy bodies, and frontotemporal lobar 2021;195:111438. degeneration: Comparison using serum albumin, total protein, [12] Lovell M.A. A Potential Role for Alterations of Zinc and and hemoglobin level. PLoS ONE. 2016;11 Zinc Transport Proteins in the Progression of Alzheimer’s [24] Colomina M.T., Peris-Sampedro F. Aluminum and Disease. J. Alzheimer’s Dis. 2009;16:471–483. Alzheimer’s disease. Adv. Neurobiol. 2017;18:183–197. [13] Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones [25] Dias HK, Brown CL, Polidori MC, Lip GY, Griffiths W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., HR. LDL-lipids from patients with hypercholesterolaemia Kim Y., et al. Treatment with a copper–zinc chelator markedly and alzheimer‘s disease are inflammatory to microvascular and rapidly inhibits beta-amyloid accumulation in Alzheimer’s endothelial cells: mitigation by statin intervention. Clin Sci
disease transgenic mice. Neuron. 2001;30:665–676. (Lond).(2015) 129(12):1195–206. [14] Maya S., Prakash T., Madhu K.D., Goli D. Multifaceted [26] Chen H, Liu S, Ji L, Wu T, Ji Y, Zhou Y, et al.. Folic acid effects of aluminium in neurodegenerative diseases: A review. supplementation mitigates alzheimer‘s disease by reducing Biomed. Pharmacother. 2016;83:746–754. inflammation: A randomized controlled trial. Mediators [15] Sharma D.R., Wani W.Y., Sunkaria A., Kandimalla R.J., Inflamm(2016) 2016:5912146. Sharma R.K., Verma D., Bal A., Gill K.D. Quercetin attenuates [27] Kounatidis I, Ligoxygakis P. Drosophila as a model system neuronal death against aluminum-induced neurodegeneration in to unravel the layers of innate immunity to infection. Open Biol
the rat hippocampus. Neuroscience. 2016;324:163–176. (2012) 2(5):120075. [16] Chen G.F., Xu T.H., Yan Y., Zhou Y.R., Jiang Y., Melcher K., [28] Jones SV, Kounatidis I. Nuclear factor-kappa b and Xu H.E. Amyloid beta: Structure, biology and structure-based Alzheimer disease, unifying genetic and environmental risk
therapeutic development. Acta Pharmacol. Sin. 2017;38:1205– factors from cell to humans. Front Immunol (2017) 8:1805. 1235. [29] MEsmaeili MA, Yadav S, Gupta RK, Waggoner GR, [17] ]Guerreiro R., Bras J. The age factor in Alzheimer’s disease. Deloach A, Calingasan NY, et al.. Preferential PPAR- Genome Med. 2015;7:106. alpha activation reduces neuroinflammation, and blocks [18] Bekris L.M., Yu C.E., Bird T.D., Tsuang D.W. Genetics of neurodegeneration in vivo. Hum Mol Genet (2016) 25(2):317– Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010;23:213– 27. 227. [30] Cummings JL, Tong G, Ballard C. Treatment Combinations [19] Cauwenberghe C., Van Broeckhoven C., Sleegers K. The for Alzheimer‘s Disease: Current and Future Pharmacotherapy genetic landscape of Alzheimer disease: Clinical implications Options. J Alzheimers Dis. 2019;67(3):779-794.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
